GlassScriptPhysician profile
Tejas Suresh
NPI 1679836365
$3,888.96
in general payments reported to CMS, 2019-2025
36 companies · $932 in 2025
The $932 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.92 · 2023: $507 · 2024: $2,438 · 2025: $932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,581 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,580.65 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,544.69 | 2023-2025 | |
| Genentech USA, INC. | $215.11 | 2023-2025 | Tecentriq, Venclexta, Columvi |
| Janssen Biotech, INC. | $173.92 | 2023-2025 | Erleada, Darzalex, Akeega |
| Pfizer INC. | $161.17 | 2023-2025 | |
| Exelixis INC. | $124.39 | 2024-2025 | Cabometyx |
| Sumitomo Pharma America, INC. | $120.95 | 2023-2024 | Orgovyx |
| Tempus Ai, INC | $112.08 | 2024 | Xt Cdx |
| Astrazeneca Pharmaceuticals LP | $108.39 | 2024-2025 | Calquence, Imfinzi, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $107.63 | 2023-2024 | Alunbrig, Vpriv, Ninlaro |
| Celgene Corporation | $105.46 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Merck Sharp & Dohme LLC | $81.39 | 2023-2024 | Keytruda, Lynparza |
| Genzyme Corporation | $77.65 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $71.82 | 2023-2024 | Xarelto |
| Incyte Corporation | $70.33 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $69.57 | 2024-2025 | Enhertu |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $68.76 | 2023-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $67.57 | 2024-2025 | Opdivo |
| Mirati Therapeutics, INC. | $66.90 | 2024 | Krazati |
| Lilly USA, LLC | $66.00 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Servier Pharmaceuticals LLC | $60.12 | 2024 | |
| Array Biopharma INC | $48.14 | 2024-2025 | Mektovi, Tukysa, Braftovi |
| Eisai INC. | $45.89 | 2024 | |
| Novocure INC. | $40.76 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Gilead Sciences, INC. | $39.22 | 2021-2024 | |
| Astellas Pharma US INC | $28.51 | 2024 | Xospata |
| Rigel Pharmaceuticals, INC. | $26.26 | 2024 | Rezlidhia, Tavalisse |
| Sobi, INC | $24.39 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.26 | 2025 | |
| Kite Pharma, INC. | $22.06 | 2023 | Yescarta |
| G1 Therapeutics, INC. | $19.16 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $18.22 | 2024 | |
| Myriad Genetic Laboratories, INC. | $16.82 | 2024 | Myrisk |
| Alexion Pharmaceuticals, INC. | $16.73 | 2023 | Ultomiris |
| Legend Biotech USA INC. | $15.39 | 2025 | Carvykti |
| Acrotech Biopharma INC. | $15.09 | 2023 | Beleodaq |
| Geron Corporation | $14.16 | 2025 | Rytelo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tejas Suresh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.